(Source: Johnson & Johnson) 4276210d-1972-426f-bab1-761478e35fc7.pdf November 3, 2015 First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Announced Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy CORK, Ireland, Nov. 3, 2015 /CNW/ - Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced that Phase IIb data studying a combination regimen of two investigational long acting, injectable formulations of HIV medicines-Janssen's rilpivirine and ViiV Healthcare's cabotegravir-given together every 4 or 8 weeks show comparable efficacy...
↧